Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Apr. 26, 2026	Apr. 27, 2025	Jan. 25, 2026
Cash flows from operating activities:
Net income	$ 26,563	$ 19,345
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	9,161	10,190
Amortization of right-of-use assets	1,574	1,346
Accretion of deferred financing costs	1,090	1,254
Write-off of deferred financing costs	0	152
Interest rate swap termination	0	14
Deferred income taxes	1,844	2,411
Share-based compensation	26,446	6,835
Loss on disposition of business operations and assets	8	26
Equity method income	(1,621)	(1,046)
Gain from sale of investments	(100)	0
Corporate-owned life insurance, net	2,393	655
Changes in assets and liabilities:
Accounts receivable, net	(14,055)	(3,107)
Inventories	(7,180)	(6,627)
Other assets	(3,155)	2,281
Accounts payable	8,044	9,805
Accrued liabilities	(13,681)	(15,444)
Other liabilities	(1,148)	(266)
Net cash provided by operating activities	36,183	27,824
Cash flows from investing activities:
Proceeds from sales of property, plant and equipment	42	0
Purchase of property, plant and equipment	(8,172)	(1,650)
Proceeds from sale of investments	100	536
Purchase of intangibles	(5,274)	(529)
Acquisition, net of cash acquired	(29,188)	0
Premiums paid for corporate-owned life insurance	0	(3,428)
Net cash used in investing activities	(42,492)	(5,071)
Cash flows from financing activities:
Proceeds from revolving line of credit	50,000	0	$ 68,300
Payments of revolving line of credit	(50,000)	0
Payments of term loans	0	(10,000)
Deferred financing costs	0	(492)
Payments for employee share-based compensation payroll taxes	(26,585)	(8,901)
Proceeds from exercise of stock options	787	32
Net cash used in financing activities	(25,798)	(19,361)
Effect of foreign exchange rate changes on cash and cash equivalents	238	1,339
Net (decrease) increase in cash and cash equivalents	(31,869)	4,731
Cash and cash equivalents at beginning of period	195,179	151,743	151,743
Cash and cash equivalents at end of period	163,310	156,474	$ 195,179
Supplemental disclosure of cash flow information:
Interest paid	346	3,526
Income taxes paid	6,735	1,335
Non-cash investing and financing activities:
Accounts payable related to capital expenditures	97	247
Accrued deferred financing costs	0	72
Accrued purchases of intangibles	172	5,130
Acquisition-related holdback amount	$ 3,400	$ 0